Treace Medical Concepts, Inc. - TMCI STOCK NEWS

Treace Medical Concepts (TMCI) reported third-quarter 2022 revenue of $33.1 million, marking a 53% increase year-over-year. The gross margin stood at 80.0%, with a gross profit of $26.4 million. Direct sales contributed 74% of total revenue, significantly up from 53% in Q3 2021. Despite this, the net loss increased to ($12.1 million), or ($0.22) per share, compared to ($6.4 million) a year earlier. Treace raised its 2022 revenue guidance to $135 million to $138 million, reflecting 43% to 46% growth over 2021.

PONTE VEDRA, Fla., Oct. 25, 2022 – Treace Medical Concepts, Inc. (TMCI), a leader in bunion surgical treatment, announced participation in two upcoming investor conferences. CEO John T. Treace and CFO Mark L. Hair will represent the company at the J.P. Morgan Equity Opportunities Forum on November 14, 2022, and at the Stifel 2022 Healthcare Conference on November 15, 2022. The latter will feature a fireside chat at 9:10 AM ET, accessible via the company’s investor relations website. Treace aims to revolutionize bunion surgery with its patented Lapiplasty® system, targeting 1.1 million surgical candidates in the U.S.

Treace Medical Concepts (NasdaqGS: TMCI) announced it will release its third quarter 2022 financial results on November 8, 2022, post-market. The company focuses on enhancing surgical treatments for bunions, affecting around 65 million Americans. They have developed the patented Lapiplasty® 3D Bunion Correction™ system and recently introduced the Adductoplasty™ Midfoot Correction System. A conference call will follow the earnings release at 4:30 PM ET, where management will discuss the results.

Treace Medical Concepts (TMCI) announced the appointments of Lance E. Berry and Jane E. Kiernan to its board of directors, effective October 1, 2022. Their extensive experience in the medical device sector is expected to enhance Treace's board capabilities. Chairman James T. Treace highlighted that their expertise will support the company's strategies in tapping a $5 billion market opportunity. The Lapiplasty® system aims to improve surgical treatments for bunions, addressing a market of around 1.1 million annual surgical candidates in the U.S.

Treace Medical Concepts (TMCI) is showcasing innovative products at the 2022 AOFAS Annual Meeting in Quebec City, from September 14-17. Key highlights include the Lapiplasty® Micro-Incision™ System, which allows for smaller surgical incisions in bunion correction, and the SpeedPlate™ Rapid Compression Implants, a new fixation technology awaiting FDA review. Additionally, the company is featuring commercially available innovations like the Lapiplasty® S4A Anatomic Plating Kit and various tissue release instruments, emphasizing its commitment to advancing surgical care for bunion patients.

Treace Medical Concepts, Inc. (NasdaqGS: TMCI) announced the interim analysis from the ALIGN3D™ clinical study during the AOFAS Annual Meeting. The study evaluated 159 patients who underwent the Lapiplasty® Procedure, revealing key results: an early return to weightbearing at an average of 8.3 days, a low recurrence rate of 1.4%, and an 81% reduction in pain after 24 months. Significant improvements were noted in patient-reported outcomes, with an 82% increase in walking/standing and 84% in social interaction. The ALIGN3D™ study continues to demonstrate the effectiveness and reliability of the Lapiplasty® Procedure.

Treace Medical Concepts (TMCI) announced that CEO John T. Treace and CFO Mark L. Hair will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 8:35 am ET. This event will highlight the company’s advancements in the surgical treatment of hallux valgus (bunions) through its patented Lapiplasty® 3D Bunion Correction™ procedure. A live webcast will be available on the company’s investor relations website.

Treace Medical Concepts (TMCI) reported strong financial results for Q2 2022, achieving $30 million in revenue, a 45% increase year-over-year. The gross margin rose to 81.1%, up 20 basis points YoY. Direct sales accounted for 68% of total sales, driven by a unique bunion-focused salesforce. The company raised its full-year revenue guidance to $130-$134 million, representing growth of 38%-42% over 2021. Despite a net loss of ($17.2 million), TMCI maintains a strong cash position of $101.5 million, bolstered by a new $150 million loan arrangement.

Treace Medical Concepts (TMCI) has launched innovative surgical technologies aimed at improving the treatment of bunions. The new products include the Lapiplasty® 3-n-1™ Cut Guide, which reduces surgical time by 15%, and the S4A Anatomic Plating Kit, designed for better anatomical fit. Additionally, SpeedRelease™ and TriTome™ Release Instruments facilitate accurate tissue release during bunion surgery. CEO John T. Treace highlighted positive early feedback and plans for wider distribution to enhance surgical outcomes nationwide.